MBPHARMACO CONSULTING LTD

Company Registration Number:
14702698 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2025

Period of accounts

Start date: 01 April 2024

End date: 31 March 2025

MBPHARMACO CONSULTING LTD

Contents of the Financial Statements

for the Period Ended 31 March 2025

Company Information - 3
Profit and Loss Account - 4
Balance sheet - 5
Additional notes - 7
Balance sheet notes - 10

MBPHARMACO CONSULTING LTD

Company Information

for the Period Ended 31 March 2025




Registered office: 4th Floor 205
Regent Street
London
England
W1B 4HB
Company Registration Number: 14702698 (England and Wales)

MBPHARMACO CONSULTING LTD

Profit and Loss Account

for the Period Ended 31 March 2025


Notes

2025
£
13 months to
31 Mar 2024
£
Turnover 219,015 128,020
Cost of sales ( 0 ) ( 0 )
Gross Profit or (Loss) 219,015 128,020
Income from coronavirus (COVID-19) business support grants 0 0
Distribution Costs ( 0 ) ( 0 )
Administrative Expenses ( 160,147 ) ( 43,623 )
Other operating income 0 0
Operating Profit or (Loss) 58,868 84,397
Interest Receivable and Similar Income 0 0
Interest Payable and Similar Charges ( 0 ) ( 0 )
Profit or (Loss) Before Tax 58,868 84,397
Tax on Profit ( 11,850 ) ( 18,615 )
Profit or (Loss) for Period 47,018 65,782

The notes form part of these financial statements

MBPHARMACO CONSULTING LTD

Balance sheet

As at 31 March 2025


Notes

2025
£
13 months to
31 Mar 2024
£
Fixed assets
Total fixed assets: - -
Current assets
Debtors: 4 5,490 3,510
Cash at bank and in hand: 84,908 89,884
Total current assets: 90,398 93,394
Creditors: amounts falling due within one year: 5 ( 12,258 ) ( 8,243 )
Net current assets (liabilities): 78,140 85,151
Total assets less current liabilities: 78,140 85,151
Total net assets (liabilities): 78,140 85,151

The notes form part of these financial statements

MBPHARMACO CONSULTING LTD

Balance sheet continued

As at 31 March 2025


Notes

2025
£
13 months to
31 Mar 2024
£
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 78,139 85,150
Shareholders funds: 78,140 85,151

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 12 April 2025
And Signed On Behalf Of The Board By:

Name: Almisbah Beerahee
Status: Director

The notes form part of these financial statements

MBPHARMACO CONSULTING LTD

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

MBPHARMACO CONSULTING LTD

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 2. Employees


    2025
    13 months to
    31 Mar 2024
    Average number of employees during the period 1 1

MBPHARMACO CONSULTING LTD

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 3. Off balance sheet disclosure

    No

MBPHARMACO CONSULTING LTD

Notes to the Financial Statements

for the Period Ended 31 March 2025

4. Debtors


2025
£
13 months to
31 Mar 2024
£
Trade debtors 5,490 3,510
Total 5,490 3,510
Debtors due after more than one year: 5,490 3,510

MBPHARMACO CONSULTING LTD

Notes to the Financial Statements

for the Period Ended 31 March 2025

5.Creditors: amounts falling due within one year note


2025
£
13 months to
31 Mar 2024
£
Taxation and social security 12,258 8,243
Total 12,258 8,243